作者
Riti Sharan, Shashank R Ganatra, Dhiraj K Singh, Journey Cole, Taylor W Foreman, Rajesh Thippeshappa, Charles A Peloquin, Vinay Shivanna, Olga Gonzalez, Cheryl L Day, Neel R Gandhi, Edward J Dick, Shannan Hall-Ursone, Smriti Mehra, Larry S Schlesinger, Jyothi Rengarajan, Deepak Kaushal
发表日期
2022/9/15
期刊
The Journal of Clinical Investigation
卷号
132
期号
18
出版商
American Society for Clinical Investigation
简介
A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI). The aim of this study is to assess 3HP-mediated clearance of M. tuberculosis bacteria in macaques with asymptomatic LTBI. Twelve Indian-origin rhesus macaques were infected with a low dose (~10 CFU) of M. tuberculosis CDC1551 via aerosol. Six animals were treated with 3HP and 6 were left untreated. The animals were imaged via PET/CT at frequent intervals. Upon treatment completion, all animals except 1 were coinfected with SIV to assess reactivation of LTBI to active tuberculosis (ATB). Four of 6 treated macaques showed no evidence of persistent bacilli or extrapulmonary spread until the study end point. PET/CT demonstrated the presence of significantly more granulomas in untreated animals relative to the treated group. The untreated animals …
引用总数
学术搜索中的文章